ClinicalTrials.gg
RecruitingNCT07388381THROMBI-CATHUpdated Jun 22, 2026

Superficial Vein Thrombosis of the Upper Limb in Bacteremia Associated With PICCline and Midline Catheters: Frequency and Clinical Consequences

An interventional study of Follow-up for catheter-related bacteremia in Catheter Associated Infection, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Catheter-Related Infections with a site in France — 4 open to participants now, 4 under way, none of them phase 3. Catheter-Related Infections · France.

Planned enrollment
8th of 10
150 · median 300
Started
2026
with 3 others
No phase
7 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
2 of 16
Centre Hospitalier Universitaire de Nice

Among the 16 studies in Catheter-Related Infections with a site in France, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 with no phase, and was the 15th registered.

Catheter-Related Infections

113 studies on the registry are indexed under Catheter-Related Infections; 19 are open to participants now.

Browse Catheter-Related Infections studies →

Open to participants now

4 of the 16 studies in Catheter-Related Infections with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 10 Catheter-Related Infections studies recruiting now, 9 (90%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Catheter-Related Infections with a site in France, or all of them as a file.
02

Study summary

The use of long-term peripheral venous catheters inserted in the upper limb (PICC lines and Midlines) has increased markedly over recent years.

Catheter-related bacteremias and venous thromboses are the main complications associated with these catheters. These events may occur independently or simultaneously. In addition, venous thromboses may involve the superficial venous system (SVT) or the deep venous system (DVT).

Current guidelines define septic thrombophlebitis as the association of a bacteremia and a DVT along the venous course of the catheter. This represents a severe complication of catheter-related bacteremia, leading to a modification in the duration of antibiotic therapy. However, SVTs associated with catheter-related bacteremias along the catheter pathway are not included in the definition of septic thrombophlebitis and are not addressed by specific recommendations.

The objective of this study is therefore to assess the impact of upper-limb SVT on the frequency of unfavorable outcomes in catheter-related bacteremias related to PICC and Midline catheters, in order to determine whether superficial venous thrombosis occurring in the context of a catheter-related bacteremia should be considered a distinct entity not falling under the diagnosis of septic thrombophlebitis (and therefore not requiring a modification of antibiotic treatment duration, in accordance with current guidelines), or whether, conversely, it should be considered equivalent to septic thrombophlebitis, as is the case for deep venous thrombosis.

03

Conditions studied

  • Catheter Associated Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Hospitalization in a department of Nice University Hospital
  • Expected length of hospitalization ≥ 72 hours
  • Diagnosis of catheter-related bacteremia on PICCline or Midline.
  • Affiliation with a social security system
  • No objection to the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Legal protection measures (patients under guardianship, trusteeship, or judicial protection)
  • Inability to remove the catheter
  • Doppler ultrasound showing DVT in the upper limb at selection.
  • Inability to perform the initial routine Doppler ultrasound
  • Withdrawal of the patient's consent
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Catheter Associated Infection

    Other: Follow-up for catheter-related bacteremia

Interventions

  • OtherFollow-up for catheter-related bacteremia

    Clinical follow-up and outcomes of patients with catheter-related bacteremia

06

What researchers measure

Primary outcomes

  1. Frequency of unfavorable outcomes according to the presence or absence of superficial venous thrombosis (SVT)

    An unfavorable outcome is defined as a composite endpoint including at least one of the following: * Relapse of bacteremia documented with the same microorganism and/or * Extension of superficial venous thrombosis to the deep venous system (deep vein thrombosis and/or pulmonary embolism) and/or * Infectious complications related to the initial diagnosis of catheter-related bacteremia, including infective endocarditis, deep abscess, septic thrombophlebitis, osteoarticular infection, or any other complication related to CRBSI, and/or * Septic shock.

    Time frame: At day 28 after completion of treatment for catheter-related bacteremia

Secondary outcomes

  1. Describe the risk factors associated with the occurrence of deep vein thrombosis.

    Comparison of patient parameters and management with the course of catheter-related bacteremia

    Time frame: At day 28 after completion of treatment for catheter-related bacteremia

  2. Describe the imaging findings and the evolution of catheter-related deep vein thrombosis

    Comparison of echo-doppler imaging between inclusion and 14 days after antibiotics treatment

    Time frame: At day 14 after completion of treatment for catheter-related bacteremia

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

Of 28 non-industry interventional studies with no phase under Catheter-Related Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 20 months is below that.

Counting every sponsor, half of 31 studies reached it within 22 months; a quarter within 13 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Feb 5, 2026
StartActual
Feb 9, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07388381
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Feb 9, 2026
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Elisa DEMONCHY
Contact
demonchy.e@chu-nice.fr
0492035847
Dylan MAZZOLENI
Contact
mazzoleni.d@chu-nice.fr
+33 7 68 25 71 76

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion